Lance Sullenberger, MD
Cardiovascular Disease · Albany, NYNPI 1174623086
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $111,075 of the $139,476 with a category attached, or 79.6%. Lilly USA, LLC accounts for 62.5% of it on its own, with 31 other manufacturers making up the rest. 2025 is the largest year on record at $66,740, more than ten times the $654 reported in 2019. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 476 payments — averaging $293.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$87K
- Boehringer Ingelheim$25K
- Novartis$16K
- Cleerly, Inc.$9K
- E.r. Squibb & Sons, L.L.C.$446
- Kiniksa Pharmaceuticals International, PLC$300
- plus $2K from 26 others
Across 8 payments — averaging $18,614 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$123K
- Amgen$19K
- Novartis$7K
- E.r. Squibb & Sons, L.L.C.$351
What the payments were for
- Consulting fees$9,0386%
- Speaking & faculty fees$111,07580%
- Travel & lodging$10,6998%
- Food & beverage$8,6646%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 89 | $87,241 |
| Boehringer Ingelheim | 34 | $25,049 |
| Novartis | 215 | $15,584 |
| Cleerly, Inc. | 4 | $8,551 |
| E.r. Squibb & Sons, L.L.C. | 22 | $446 |
| Kiniksa Pharmaceuticals International, PLC | 12 | $300 |
| Pfizer | 12 | $218 |
| Kiniksa Pharmaceuticals, Ltd. | 16 | $201 |
| Merck | 10 | $177 |
| Celonova Biosciences, Inc. | 1 | $176 |
| Alnylam Pharmaceuticals Inc. | 1 | $123 |
| Altathera Pharmaceuticals LLC | 1 | $122 |
| Abbott | 6 | $115 |
| AstraZeneca | 7 | $113 |
| Boston Scientific | 2 | $111 |
| Lexicon Pharmaceuticals, Inc. | 6 | $105 |
| Arineta, Inc | 1 | $91 |
| Cvrx, Inc. | 5 | $84 |
| Bridgebio Pharma, Inc. | 4 | $83 |
| GE HealthCare | 2 | $72 |
| Johnson & Johnson | 3 | $66 |
| Astellas Pharma US Inc | 3 | $61 |
| Scpharmaceuticals Inc. | 3 | $54 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $51 |
| Infobionic, Inc | 1 | $49 |
| Bard Peripheral Vascular, Inc. | 1 | $46 |
| Novo Nordisk | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Chiesi USA, Inc. | 1 | $20 |
| Bayer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$139,476 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,578 | $2,330,578 |
| JardianceEmpagliflozin | 649 | $979,352 |
| Repatha SureclickEvolocumab | 561 | $698,837 |
| EntrestoSacubitril/Valsartan | 359 | $544,644 |
| XareltoRivaroxaban | 221 | $311,351 |
| OzempicSemaglutide | 197 | $224,480 |
| WegovySemaglutide | 113 | $164,617 |
| Praluent PenAlirocumab | 181 | $136,335 |
| FarxigaDapagliflozin Propanediol | 77 | $114,847 |
| MounjaroTirzepatide | 94 | $104,938 |
| MultaqDronedarone Hcl | 58 | $94,182 |
| Droxidopa | 17 | $71,677 |
| Atorvastatin Calcium | 3,596 | $41,502 |
| Rosuvastatin Calcium | 2,346 | $41,417 |
| Metoprolol Succinate | 2,305 | $35,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $218 | $2,330,5781,578 claims |
| Boehringer IngelheimJardiance | $25,049 | $979,352649 claims |
| NovartisEntresto | $15,584 | $544,644359 claims |
| Novo NordiskOzempic, Wegovy | $43 | $389,097310 claims |
| Johnson & JohnsonXarelto | $66 | $311,351221 claims |
| AstraZenecaFarxiga, Brilinta | $113 | $142,329101 claims |
| Lilly USA, LLCMounjaro | $87,241 | $104,93894 claims |
| Sanofi-aventis U.S. LLCMultaq | $24 | $94,18258 claims |
| MerckVerquvo | $177 | $23,28521 claims |
| Esperion Therapeutics, Inc.Nexlizet | $41 | $10,04012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Albany
- Augustin DelagoAlbany$1.8M
- Rizwan AlimohammadAlbany$349K
- Edward PhilbinAlbany$226K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.